Mack Roach III, MD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Mack Roach III, MD

Professor and Chair, Department of Radiation Oncology, and Professor, Department of Urology, UCSF

Phone: (415) 353-9807 (appts)
Box 1708, UCSF
San Francisco, CA 94143-1708

View on UCSF Profiles

Cancer Center Membership

Program Member » Prostate Cancer» Cancer Control

Education

Morehouse College, Atlanta, GA, BS, 1975, Physics
Stanford University School of Medicine, Stanford,CA, MD, 1979, Medicine
University of California San Francisco, Fellow, 1981-83, Med Oncology
Stanford University School of Medicine, Stanford,CA, Resident, 1984-87, Radiation Oncology


Professional Experience

  • 1987-1988
    Acting Chief, Radiation Oncology Service, VA Medical Center, Martinez, CA
  • 1988-1990
    Chief, Radiation Oncology Service, VA Medical Center, Martinez, CA
  • 1990-1994
    Assistant Professor, Department of Radiation Oncology, UCSF
  • 1994-2000
    Associate Professor, Department of Radiation Oncology, UCSF
  • 2000-present
    Professor, Department of Radiation Oncology & Urology, UCSF
  • 2003-2007
    Vice Chair, Department of Radiation Oncology, UCSF
  • 2006-2007
    Interim Chair, Department of Radiation Oncology
  • 2007-present
    Chair, Department of Radiation Oncology

Honors & Awards

  • 1980-1981
    Outstanding Intern of the Year (Charles R. Drew Award)
  • 1981-1982
    Fellow of the American Cancer Society
  • 1994
    UCSF Health Net Wellness Award
  • 1994-1997
    American Cancer Society Career Development Award
  • 1996-97; 1997-98; 2001-02
    "The Best Doctors in America"
  • 2002
    Fellow, American College of Radiology
  • 2002-05
    President, John Hale Medical Society
  • 2005
    10 Most Influential African Americans in the Bay Area (Healthcare)

Selected Publications

  1. Outcomes of hypofractionated stereotactic body radiotherapy boost for intermediate and high-risk prostate cancer. Radiat Oncol. 2016; 11(1):8.
    View on PubMed
  2. Prostate Cancer, Version 1.2016. J Natl Compr Canc Netw. 2016 Jan; 14(1):19-30.
    View on PubMed
  3. Radical Prostatectomy Versus Radiation and Androgen Deprivation Therapy for Clinically Localized Prostate Cancer: How Good Is the Evidence? Int J Radiat Oncol Biol Phys. 2015 Dec 1; 93(5):1064-70.
    View on PubMed
  4. Knowledge and attitudes regarding clinical trials and willingness to participate among prostate cancer patients. Contemp Clin Trials. 2015 Oct 1.
    View on PubMed
  5. Patient- and treatment-specific predictors of genitourinary function after high-dose-rate monotherapy for favorable prostate cancer. Brachytherapy. 2015 Jul 18.
    View on PubMed
  6. Reporting of results in DART01/05 GICOR. Lancet Oncol. 2015 Jun; 16(6):e258.
    View on PubMed
  7. Postoperative radiation therapy for patients at high-risk of recurrence after radical prostatectomy: does timing matter? BJU Int. 2015 Nov; 116(5):713-20.
    View on PubMed
  8. Patterns of Local Failure following Radiation Therapy for Prostate Cancer. J Urol. 2015 Oct; 194(4):977-82.
    View on PubMed
  9. Postprostatectomy Radiotherapy for Patients with High-risk Features on Definitive Pathology: A Plea for Evidence-based Medicine. Eur Urol. 2015 Nov; 68(5):775-6.
    View on PubMed
  10. Dose-volume analysis and the temporal nature of toxicity with stereotactic body radiation therapy for prostate cancer. Pract Radiat Oncol. 2015 Sep-Oct; 5(5):e465-72.
    View on PubMed
  11. Bladder wall recurrence of prostate cancer after high-dose-rate brachytherapy. Brachytherapy. 2015 Mar-Apr; 14(2):185-8.
    View on PubMed
  12. Impact of biochemical failure classification on clinical outcome: A secondary analysis of Radiation Therapy Oncology Group 9202 and 9413. Cancer. 2015 Mar 15; 121(6):844-52.
    View on PubMed
  13. Natural History after Biochemical Failure Following Dose-escalated External Beam Radiation: An Opportunity to Improve Outcomes? Eur Urol. 2015 Jun; 67(6):1017-8.
    View on PubMed
  14. Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature. Eur Urol. 2015 May; 67(5):852-63.
    View on PubMed
  15. Pre-plan parameters predict post-implant D90 = 140 Gy for (125)I permanent prostate implants. J Contemp Brachytherapy. 2014 Jun; 6(2):143-53.
    View on PubMed
  16. Quality improvement of International Classification of Diseases, 9th revision, diagnosis coding in radiation oncology: Single-institution prospective study at University of California, San Francisco. Pract Radiat Oncol. 2015 Jan-Feb; 5(1):e45-51.
    View on PubMed
  17. High-risk prostate cancer-classification and therapy. Nat Rev Clin Oncol. 2014 Jun; 11(6):308-23.
    View on PubMed
  18. Prostate cancer, version 2.2014. J Natl Compr Canc Netw. 2014 May; 12(5):686-718.
    View on PubMed
  19. Radium-223 vs EBRT for multiple painful bone metastases: is less more? Oncology (Williston Park). 2014 Apr; 28(4):297-8.
    View on PubMed
  20. Radical prostatectomy v radiation: only a randomised trial can provide the answer. BMJ. 2014; 348:g2266.
    View on PubMed

Go to UCSF Profiles, powered by CTSI